Comparison of neoadjuvant chemoimmunotherapy with or without concurrent radiotherapy for locally advanced resectable esophageal squamous cell carcinoma: a multicenter retrospective study
Diseases of the Esophagus · 02.03.2026 · 39 (2)
DOI: 10.1093/dote/doag013 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Diseases of the Esophagus, online erschienen am 30.04.2026. Verfasst von Huanghe He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disea…. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Chemoradiotherapy. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
The aim of this study was to evaluate the safety and clinical benefits of adding concurrent radiotherapy to neoadjuvant chemoimmunotherapy in patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC). This multicenter retrospective study enrolled eligible ESCC patients treated between November 2019 and July 2020 from four hospitals. Baseline characteristics were collected, and patients were categorized into two groups based on neoadjuvant regimens: the chemoimmunotherapy group (CI group) and the chemoimmunotherapy with concurrent radiotherapy group (CIR group). Treatment-related complications, surgical outcomes, pathological response, tumor recurrence, and survival were analyzed. A total of 78 eligible patients were included: 49 in the CI group and 29 in the CIR group. Baseline characteristics (age, sex, clinical stage, cardiopulmonary function) were balanced between groups. During neoadjuvant therapy, the CI group had significantly lower incidences of grade 3 and grade 4 leukopenia/neutropenia (15/49 vs. 15/29, P = 0.025), and lower incidences of grade 3 and grade 4 checkpoint inhibitor pneumonitis (CIP) (1/49 vs. 8/29, P = 0.002). All CI group patients achieved R0 resection after 1–3 neoadjuvant cycles versus 24/29 in the CIR group (P > 0.05). The CIR group showed higher major pathological response (including pathological complete response) rates (16/24 vs. 10/49), though statistically non-significant (P = 0.121). No significant differences were observed in 5-year progression-free survival or overall survival. Adding concurrent radiotherapy to neoadjuvant chemoimmunotherapy increased hematologic toxicity and CIP in resectable locally advanced ESCC patients, without conferring survival benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangz…
- Department of Thoracic Surgery, Anyang Tumor Hospital, Anyang City, China.
- Department of Anesthesiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
- Department of Gastroenterology, Longmen County People's Hospital, Huizhou City, China.
ORCID-Profile: Huanghe He
Zitieren
APA
He, H., Xu, B., Liu, H., Le, C., Zhu, Y., Zhang, Y., Huang, S., Liu, J., & He, J. (2026). Comparison of neoadjuvant chemoimmunotherapy with or without concurrent radiotherapy for locally advanced resectable esophageal squamous cell carcinoma: a multicenter retrospective study. Diseases of the Esophagus, 39(2). https://doi.org/10.1093/dote/doag013
Vancouver
He H, Xu B, Liu H, Le C, Zhu Y, Zhang Y, et al. Comparison of neoadjuvant chemoimmunotherapy with or without concurrent radiotherapy for locally advanced resectable esophageal squamous cell carcinoma: a multicenter retrospective study. Diseases of the Esophagus. 2026;39(2). doi:10.1093/dote/doag013
BibTeX
@article{He2026,
author = {He, Huanghe and Xu, Bing and Liu, Hui and Le, Cheng and Zhu, Yaping and Zhang, Yangyang and Huang, Sihe and Liu, Jun and He, Jianxing},
title = {Comparison of neoadjuvant chemoimmunotherapy with or without concurrent radiotherapy for locally advanced resectable esophageal squamous cell carcinoma: a multicenter retrospective study},
journal = {Diseases of the Esophagus},
year = {2026},
volume = {39},
number = {2},
doi = {10.1093/dote/doag013}
}
EUVIMED